Web version

 
 

GE Healthcare

 

Elevating Molecular Imaging

 
 

"It is easy to predict a bright future, both for PSMA imaging and therapy, as we have seen results that
are absolutely incredible"

 

Stefano Fanti, Professor of Diagnostic Imaging at University
of Bologna, Italy.

 
 

Prostate cancer is the most common cancer in men in Europe. Improved treatment of non-metastatic disease has enabled to reduce mortality rate by 40% since 1994. But the management of patients with metastatic prostate cancer and biochemical recurrence is still a challenge.

 

As commented by Joe O’Sullivan, Professor of Radiation Oncology, Queen's University Belfast and a Consultant Oncologist at Northern Ireland Cancer Centre, Belfast (Ireland):

 

"Today it can be very difficult to identify patients with oligometastases. If we can identify these patients with a very sensitive tracer such as PSMA, we may be able to offer more treatment options to them."

 

You want to know more about
the future of PET PSMA imaging?

 
 
 

Integrating this trend, the European Association of Urology updated its
evidence-based recommendations on prostate cancer in 2019. The guidelines now
include PSMA PET/CT as the preferred imaging method at biochemical recurrence or persistent PSA.

 
 

You want to discover how PSMA is writing
a new chapter in PET prostate imaging?

 

> WATCH VIDEOS

 
 

Prof. Stefano Fanti

 
 

Prof. Joe O’Sullivan

 
                                                           
 
 Do not reply to this email as it was sent from an unmonitored account.
 
Unsubscribe from the Breaking News.
 
Reset your password.
 
Contact auntminnieeurope.com support.
 
AuntMinnieEurope.com Privacy Policy
  
Email sent to: .
 

AuntMinnieEurope.com, 1350 North Kolb Road, Suite 215, Tucson, AZ 85715 USA
+1 520-298-1000